TrialClinical infectious diseases : an official publication of the Infectious Diseases Society of America2010

Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials.

Roy T Steigbigel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.